Naloxegol Oxalate and Zykadia

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme. When a single 25 mg dose of naloxegol was administered during multiple dosing of 400 mg once daily ketoconazole, a potent CYP450 3A4 inhibitor, naloxegol peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 9.6- and 12.9-fold, respectively. Increased exposure to naloxegol may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning. MANAGEMENT: Concomitant use of naloxegol with potent CYP450 3A4 inhibitors such as clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and protease inhibitors is considered contraindicated. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme. When a single 25 mg dose of naloxegol was administered during multiple dosing of 400 mg once daily ketoconazole, a potent CYP450 3A4 inhibitor, naloxegol peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 9.6- and 12.9-fold, respectively. Increased exposure to naloxegol may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.

MANAGEMENT: Concomitant use of naloxegol with potent CYP450 3A4 inhibitors such as clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and protease inhibitors is considered contraindicated.

Naloxegol Oxalate

Generic Name: naloxegol

Brand name: Movantik

Synonyms: Naloxegol

What is Naloxegol Oxalate?

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

What is Zykadia?